Werbung
Werbung

ARCT

ARCT logo

Arcturus Therapeutics Holdings Inc. Common Stock

6.78
USD
Gesponsert
+0.01
+0.16%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Vor-Markt

6.75

-0.03
-0.43%

ARCT Ergebnisberichte

Positives Überraschungsverhältnis

ARCT übertreffen die 25 der letzten 39Schätzungen.

64%

Nächster Bericht

Datum des nächsten Berichts
04. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$18.24M
/
-$0.68
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+6.32%
/
+38.78%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-19.90%
/
-38.74%

Arcturus Therapeutics Holdings Inc. Common Stock earnings per share and revenue

On 10. Nov. 2025, ARCT reported earnings of -0.49 USD per share (EPS) for Q3 25, beating the estimate of -0.83 USD, resulting in a 41.65% surprise. Revenue reached 17.15 million, compared to an expected 21.62 million, with a -20.67% difference. The market reacted with a -1.25% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of -0.68 USD, with revenue projected to reach 18.24 million USD, implying an increase of 38.78% EPS, and increase of 6.32% in Revenue from the last quarter.
FAQ
For Q3 2025, Arcturus Therapeutics Holdings Inc. Common Stock reported EPS of -$0.49, beating estimates by 41.65%, and revenue of $17.15M, -20.67% below expectations.
The stock price moved down -1.25%, changed from $8.78 before the earnings release to $8.67 the day after.
The next earning report is scheduled for 04. März 2026.
Based on 13 analysts, Arcturus Therapeutics Holdings Inc. Common Stock is expected to report EPS of -$0.68 and revenue of $18.24M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung